๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Dalian
Clinical trial register · China

Clinical Trials in Dalian, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca17 The First Affiliated Hospital of Dalian Medical University6 Sun Yat-sen University4 Beijing Anzhen Hospital4 Boehringer Ingelheim3
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Dalian

138 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
NCT05642780Solid Tumor
Klus Pharma Inc.
Phase 2
240
Guangzhou, Nanning, Wuhan, Changsha, Changchun, Dalian, Weifang, Xiโ€™an
2023-01-17
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Active, closed
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block
The First Affiliated Hospital with Nanjing Medical University
Not applicable
50
Beijing, Fuzhou, Nanjing, Dalian, Chengdu, Wenzhou
2022-10-14
Active, closed
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT07226752Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Recruiting
Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
NCT05325034Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia
Stephen Nicholls
Not applicable
2,000
Dalian
2022-09-15
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC
Phase 1/2
225
Dalian, Guangzhou, Hangzhou, Wuhan
2022-07-29
Active, closed
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
NCT05460273Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Active, closed
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
NCT05464433Extranodal Natural Killer T Cell Lymphoma
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Active, closed
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
NCT05195632Non-Small Cell Lung Cancer
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Recruiting
A Prognostic Model for Drug-induced Liver Injury in China
NCT05060289Drug-induced Liver Injury
Beijing Friendship Hospital
Observational
3,000
Beijing, Dalian, Guangxi, Hebei, Jiaozuo, Lanzhou, Qingdao, Qinghai
2022-05-25
Recruiting
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
NCT04662918GastroIntestinal Bleeding
Xingshun Qi
Observational
3,000
Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan
2022-01-01
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-08-14
Recruiting
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
NCT04136782Breast Cancer
Shengjing Hospital
Phase 4
110
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
NCT04476485Breast Cancer
Shengjing Hospital
Observational
1,000
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Active, closed
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
Phase 3
440
Beijing, Xiamen, Guangzhou, Zhengzhou, Changchun, Dalian, Shanghai, Chengdu
2020-09-16
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Baoding, Beijing, Changchun, Changsha, Dalian, Foshan, Fuzhou, Guangzhou
2020-07-24
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
AstraZeneca
Phase 3
805
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangdong, Guangzhou
2020-05-05
Active, closed
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
NCT03934567Lymphoma, Follicular
Xynomic Pharmaceuticals, Inc.
Phase 2
87
Beijing, Changchun, Chengdu, Dalian, Fuzhou, Guangzhou, Hainan, Hangzhou
2020-04-22
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
818
Baoding, Beijing, Changchun, Chongqing, Dalian, Foshan, Gongshu District, Guangzhou
2020-04-16
Recruiting
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT06342440Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma
City of Hope Medical Center
Observational
2,000
Dalian
2020-03-15
Recruiting
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
Janssen Research & Development, LLC
Phase 2/3
1,064
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou
2019-09-26
Recruiting
Toripalimab๏ผˆJS001๏ผ‰ as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
NCT03810339Solid Tumor, Advanced Cancer
Sun Yat-sen University
Phase 2
35
Guangzhou, Guiyang, Wuhan, Dalian
2019-01-15
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
AstraZeneca
Phase 3
1,407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2019-01-04
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Recruiting
Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
NCT04025164Breast Cancer
Fudan University
Not applicable
4,052
Guiyang, Suzhou, Dalian, Shanghai
2018-07-01
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Recruiting
Bispectral-Electroencephalography (EEG) in First Time Hemodialysis
NCT03276273Renal Failure Acute Chronic
Suez Canal University
Observational
20
Dalian
2017-05-01
Active, closed
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840Lymphoma, Mantle Cell
Acerta Pharma BV
Phase 3
635
Beijing, Changchun, Changsha, Chongqing, Dalian, Gongshu District, Haidian District, Harbin
2017-04-05
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Recruiting
Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis
NCT03244293Sepsis, Severe
Suez Canal University
Observational
20
Dalian
2014-01-01
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Nanning, Chengdu, Beijing, Dalian, Guangzhou, Hangzhou, Harbin, Kunming
2012-01
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Medtronic
Observational
20,000
Beijing, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming
1983-01
Rows per page Showing 101–138 of 138
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/dalian?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 138 of those studies with a site in Dalian.

How many clinical trials are recruiting in Dalian?

86 of the 138 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 15 have not yet opened recruitment, 33 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.